Q-omics provides the consensus-scored ZNF808 profile across patient tissues and cancer cell-line models. ZNF808 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ZNF808 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, ZNF808 RNA expression shows 21,812 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, THCA, and UVM as cancer lineages where ZNF808 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF808 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF808 survival associations across molecular data types. ZNF808 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF808 RNA expression–survival associations across cancer types. High ZNF808 expression shows unfavorable associations in LGG, LUSC, ACC, READ and MESO, but favorable associations in SCLC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ZNF808 RNA expression.
This table summarizes ZNF808 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF808. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF808 shows lower tumor expression in THCA and KIRC and higher tumor expression in CHOL, LIHC, ESCA and STAD. The THCA box plot shows higher ZNF808 RNA expression in normal versus tumor tissue (log2 FC = −0.691, t-test p < 0.001).
This table shows molecular features associated with ZNF808 in patient tissues and cancer cell lines. In patient samples, ZNF808 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF808 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
